Results 141 to 149 of about 166 (149)

Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison

European Journal of Health Economics, 2014
Marta Péntek, Valentin Brodszky, Zoltan Szekanecz   +2 more
exaly  

EE339 The Biosimilars’ Economic Evaluation in Contrast With Judicializations’ Economic Impacts of the Pharmaceutical Assistance in Brazil

Value in Health
E Tanaka, GK Tanaka, L. Assunção-Costa, E Blay   +3 more
openaire   +1 more source

How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?

Clinical Diabetes, 2017
exaly  

The Japan PDMA will require pharmaceutical companies to include risk management plans in all applications, for new drug or biosimilar products,

Reactions Weekly, 2012
openaire   +2 more sources

A randomised, crossover trial exploring the patient perspective and effectiveness of biosimilar adalimumab transition: IBD reference and biosimilar adalimumab cross over study (iBaSS)

International Journal of Clinical Pharmacy
João Gonçalves, Fraser Cummings, Susan Latter   +2 more
exaly  

4CPS-259 Impact of switching to biosimilar etanercept in rheumatoid arthritis patients followed in pharmaceutical consultations at a tertiary hospital

Section 4: Clinical pharmacy services
MJ Carvalho, AR Lopes Calvo, J Oliveira, MR Vaz, MR Ferreira, P Soares   +5 more
openaire   +1 more source

Japanese regulation of biosimilar products: past experience and current challenges

British Journal of Clinical Pharmacology, 2016
exaly  

Pharmaceutical Patent Litigation and the Emerging Biosimilars: A Conversation with Kevin M. Nelson, JD.

American health & drug benefits
openaire   +1 more source

An assessment of the inter-relationships between European patent litigation, regulation and the arrival of biosimilar pharmaceuticals on the European market

2016
openaire   +1 more source